CBIO - GLYCOMIMETICS INC

24.57
2.880   11.722%

Share volume: 543,931
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$21.69
2.88
0.13%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 2%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
15.46%
1 Month
122.55%
3 Months
80.26%
6 Months
93.01%
1 Year
10,747.68%
2 Year
1,265.00%
Key data
Stock price
$24.57
P/E Ratio 
0.00
DAY RANGE
$20.40 - $24.73
EPS 
-$10.40
52 WEEK RANGE
$0.15 - $24.73
52 WEEK CHANGE
$10,193.26
MARKET CAP 
164.765 M
YIELD 
N/A
SHARES OUTSTANDING 
27.557 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
0.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$300,179
AVERAGE 30 VOLUME 
$271,931
Company detail
CEO: Harout Semerjian
Region: US
Website: glycomimetics.com
Employees: 50
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

GlycoMimetics, Inc. focuses on the discovery and development of novel glycomimetic drugs. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.

Recent news